Phaseline

Targets › PLAT

PLAT (Tissue-type plasminogen activator): drug programs, companies and trials

16 programs from 16 companies in 70 trials: 37 Phase 3, 21 Phase 2, 9 Phase 4, 3 Phase 1; Neurology, Cardiovascular, Respiratory; next expected readout Dec 2026.

Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. (UniProt, P00750)

Open in Phaseline: the race on PLAT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of CalgaryCBD 100 mg OD
Interleukin-23 inhibitor
CNR1, PLAT, IL12B, IL23A, ADRB2, HTR2A, NR3C1, TNF, PTGS2, PTGS1Phase 4Copd; Ehlers-Danlos Syndrome; Crohn Disease; Vasovagal Syncope …Dec 2026
Amsterdam UMCAlteplase
Tissue-type plasminogen activator exogenous protein
PLATPhase 4Empyema, PleuralOct 2028
Insel Gruppe AG, University Hospital BernAlteplase
Tissue-type plasminogen activator exogenous protein
PLATPhase 4Ischemic StrokeJan 2029
Second Affiliated Hospital, Zhejiang University, School of MedicineAlteplase
Tissue-type plasminogen activator exogenous protein
PLATPhase 3Acute Ischemic StrokeDec 2026
CSPC Mingfule Pharmaceutical (Guangzhou)Tenecteplase
Tissue-type plasminogen activator exogenous protein
PLATPhase 3Acute Ischemic Stroke; ST-segment Elevation Myocardial Infarction (STEMI); Ischemic Stroke; Stroke, Ischemic …Sep 2027
Boehringer IngelheimTenecteplase
Tissue-type plasminogen activator exogenous protein
PLATPhase 3Acute Ischemic StrokeOct 2027
Assistance Publique - Hôpitaux de ParisAlteplase
Tissue-type plasminogen activator exogenous protein
PLATPhase 3Pulmonary EmbolismMar 2028
Jesper KjaergaardAlteplase
Tissue-type plasminogen activator exogenous protein
PLATPhase 3Pulmonary EmbolismJun 2028
Central Hospital, Nancy, FranceAlteplase
Tissue-type plasminogen activator exogenous protein
PLATPhase 3Stroke, Acute IschemicSep 2028
King's College Hospital NHS TrustAlteplase
Tissue-type plasminogen activator exogenous protein
PLATPhase 3Eye DiseasesDec 2028
Guri HagbergAlteplase
Tissue-type plasminogen activator exogenous protein
PLATPhase 3StrokeDec 2028
115 People's HospitalAlteplase
Tissue-type plasminogen activator exogenous protein
PLATPhase 3Stroke, Acute IschemicDec 2028
Yongjun WangReteplase
Tissue-type plasminogen activator exogenous protein
PLATPhase 3Acute Ischemic StrokeMar 2029
Copenhagen University Hospital, RigshospitaletAlteplase
Tissue-type plasminogen activator exogenous protein
PLATPhase 3Pulmonary Embolism–
South West Sydney Local Health DistrictAlteplase
Tissue-type plasminogen activator exogenous protein
PLATPhase 2Acute Respiratory FailureDec 2026
Children's National Research InstituteAminocaproic Acid
Plasminogen inhibitor; Tissue-type plasminogen activator inhibitor
PLG, PLATPhase 2CraniosynostosisJan 2028

Conditions

Acute Ischemic Stroke (13) Ischemic Stroke (6) Stroke (5) Stroke, Acute Ischemic (4) Stroke, Ischemic (4) Pulmonary Embolism (3) Ischemic Stroke, Acute (2) Musculoskeletal Injury (2) Microscopic Colitis (2) Investigating the Importance of the Subjective Psychedelic Experience (2) ST-segment Elevation Myocardial Infarction (STEMI) (1) Minor Ischemic Stroke (1)

Modalities

protein or peptide (9), small molecule (6), mixed (1)

Companies

Insel Gruppe AG, University Hospital Bern (1) Guri Hagberg (1) Central Hospital, Nancy, France (1) CSPC Mingfule Pharmaceutical (Guangzhou) (1) King's College Hospital NHS Trust (1) South West Sydney Local Health District (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Jesper Kjaergaard (1) University of Calgary (1) Amsterdam UMC (1) Boehringer Ingelheim (1) Assistance Publique - Hôpitaux de Paris (1) 115 People's Hospital (1) Copenhagen University Hospital, Rigshospitalet (1) Yongjun Wang (1) Children's National Research Institute (1)

Related targets

CNR1 (1) IL12B (1) IL23A (1) ADRB2 (1) HTR2A (1) NR3C1 (1) TNF (1) PTGS2 (1) PTGS1 (1) PLG (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.